For the common meaning of "anorexic", see Anorexia nervosa.
An anorectic or anorexic is a drug which reduces appetite, resulting in lower food consumption, leading to weight loss.[1] By contrast, an appetite stimulant is referred to as orexigenic.
The term is (from the Greek ἀν- (an-) = "without" and ὄρεξις (órexis) = "appetite"), and such drugs are also known as anorexigenic, anorexiant, or appetite suppressant.
Contents
1History
2Public health concerns
2.1Non-pharmacological alternatives
3List of anorectics
4References
5See also
6External links
History
Used on a short-term basis clinically to treat obesity, some appetite suppressants are also available over-the-counter. Most common natural appetite suppressants are based on Hoodia, a genus of 13 species in the flowering plant family Apocynaceae, under the subfamily Asclepiadoideae. Several appetite suppressants are based on a mix of natural ingredients, mostly using green tea as its basis, in combination with other plant extracts such as fucoxanthin, found naturally in seaweed. Drugs of this class are frequently stimulants of the phenethylamine family, related to amphetamine (informally known as speed).
The German and Finnish[2] militaries issued amphetamines to soldiers commonly to enhance warfare during the Second World War.[3] Following the war, amphetamines were redirected for use on the civilian market. Indeed, amphetamine itself was sold commercially as an appetite suppressant until it was outlawed in most parts of the world in the late 1950s because of safety issues. Many amphetamines produce side effects, including addiction, tachycardia and hypertension,[4] making prolonged unsupervised use dangerous.
Public health concerns
Epidemics of fatal pulmonary hypertension and heart valve damage associated with pharmaceutical anorectic agents have led to the withdrawal of products from the market. This was the case with aminorex in the 1960s, and again in the 1990s with fenfluramine (see: Fen-phen).[5] Likewise, association of the related appetite suppressant phenylpropanolamine with hemorrhagic stroke led the Food and Drug Administration (FDA) to request its withdrawal from the market in the United States in 2000, and similar concerns regarding ephedrine resulted in an FDA ban on its inclusion in dietary supplements in 2004. A Federal judge later overturned this ban in 2005 during a challenge by supplement maker Nutraceuticals. It is also debatable as to whether the ephedrine ban had more to do with its use as a precursor in methamphetamine manufacture rather than health concerns with the ingredient as such.
Non-pharmacological alternatives
Weight loss effects of water have been subject to some scientific research.[6] Drinking water prior to each meal may help in appetite suppression. Consumption of 500 mL (approximately 17 fl oz) of water 30 minutes before meals has been correlated with modest weight loss (1–2 kg) in obese men and women over a period of 8 to 12 weeks.[7][8]
List of anorectics
Numerous pharmaceutical compounds are marketed as appetite suppressants.
The following drugs listed as "centrally-acting antiobesity preparations" in the Anatomical Therapeutic Chemical Classification System:[9]
Amfepramone (also known as diethylpropion)
Bupropion and naltrexone (combination)
Caffeine
Cathine
Clobenzorex
Dexfenfluramine† (the D-enantiomer of fenfluramine; withdrawn for the same reason as its racemate)
Ephedrine (combinations)
Etilamfetamine
Fenfluramine† (one of the two components [the other being phentermine] of Fen-phen. Since discontinued to its potential for causing valvulopathies and pulmonary hypertension)
Lorcaserin
Mazindol
Mefenorex
Phentermine
Sibutramine† (in some countries withdrawn from the market because of concerns regarding its cardiovascular effects)
The following are listed as appetite depressants by MeSH, an index of medical journal articles and books.[10]
Benfluorex
Butenolide
Diethylpropion
FG-7142
Phenmetrazine† (withdrawn in some countries due to the danger of addiction)
Phentermine
Phenylpropanolamine
Pyroglutamyl-histidyl-glycine
Sibutramine
Other compounds with known appetite suppressant activity include:
Amphetamine sulfate (also known as amfetamine) – USFDA-approved for the treatment of exogenous obesity under the brand name "Evekeo".[11]
Cocaine[12]
Methamphetamine hydrochloride – USFDA-approved for the treatment of obesity (as a short-term) under the brand name "Desoxyn".[13]
References
^Lemke, Thomas L.; Williams, David A., eds. (2012). "Anorexiants as Pharmacologic Agents in the Management of Obesity". Foye's Medicinal Chemistry. pp. 1451–6. ISBN 978-1-60913-345-0.
^fi:Pervitiini
^Ulrich, Andreas (May 6, 2005). "The Nazi Death Machine: Hitler's Drugged Soldiers". Spiegel Online. Retrieved 2011-01-05.
^Abenhaim, Lucien; Moride, Yola; Brenot, François; Rich, Stuart; Benichou, Jacques; Kurz, Xavier; Higenbottam, Tim; Oakley, Celia; Wouters, Emil; Aubier, Michel; Simonneau, Gérald; Bégaud, Bernard (1996). "Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension". New England Journal of Medicine. 335 (9): 609–16. doi:10.1056/NEJM199608293350901. PMID 8692238.
^Fishman, A. P. (1999). "Aminorex to Fen/Phen : An Epidemic Foretold". Circulation. 99 (1): 156–61. doi:10.1161/01.cir.99.1.156. PMID 9884392.
^Handbook of Non Drug Intervention (HANDI) Project Team (2013). "Pre-meal water consumption for weight loss". Australian family physician. 42 (7): 478. PMID 23826600.
^Dennis, Elizabeth A.; Dengo, Ana Laura; Comber, Dana L.; Flack, Kyle D.; Savla, Jyoti; Davy, Kevin P.; Davy, Brenda M. (2009). "Water Consumption Increases Weight Loss During a Hypocaloric Diet Intervention in Middle-aged and Older Adults". Obesity. 18 (2): 300–7. doi:10.1038/oby.2009.235. PMC 2859815. PMID 19661958.
^Vij, Vinu Ashokkumar; Joshi, Anjalis (2014). "Effect of excessive water intake on body weight, body mass index, body fat, and appetite of overweight female participants". Journal of Natural Science, Biology and Medicine. 5 (2): 340–4. doi:10.4103/0976-9668.136180. PMC 4121911. PMID 25097411.
^ATC/DDD Index
^MeSH list of agents 82001067
^"Evekeo Prescribing Information" (PDF). Arbor Pharmaceuticals LLC. April 2014. pp. 1–2. Retrieved 9 January 2017.
^Wood, Douglas M; Emmett-Oglesby, Michael W (1988). "Substitution and cross-tolerance profiles of anorectic drugs in rats trained to detect the discriminative stimulus properties of cocaine". Psychopharmacology. 95 (3): 364–8. doi:10.1007/BF00181948. PMID 3137623.
^"Desoxyn Prescribing Information" (PDF). United States Food and Drug Administration. December 2013. Retrieved 9 January 2017.
See also
Anti-obesity medication
External links
Anorectics at the US National Library of Medicine Medical Subject Headings (MeSH)
Mitchell, Kari (January 1997). "Anorexiant Agents: Considerations for Use" (PDF). Drug Therapy Topics. University of Washington Medical Center. Retrieved 25 December 2013.
v
t
e
Antiobesity agents/Anorectics (A08)
Central
Stimulants
4-Methylamphetamine‡
Amfecloral
Amfepentorex
Amfepramone
Aminorex‡
Amphetamine
Amphetaminil
Atomoxetine
Benfluorex‡
Benzphetamine
Bupropion (+naltrexone; +zonisamide†)
Cathine
Cathinone
Chlorphentermine
Ciclazindol
Clobenzorex
Cloforex
Clominorex
Clortermine
Dexfenfluramine‡
Dextroamphetamine
Dexmethylphenidate
Difemetorex‡
Dimethylcathinone
Ephedrine
Ephedra‡
Etilamfetamine
Etolorex
Fenbutrazate
Fencamfamin
Fenethylline
Fenfluramine‡ (+phentermine‡)
Fenproporex
Fludorex
Fluminorex
Furfenorex‡
Indanorex
Khat
Levopropylhexedrine
Lisdexamfetamine
Manifaxine
Mazindol
Mefenorex
Methamphetamine
Methylphenidate
Norfenfluramine
Pemoline
Pentorex
Phendimetrazine
Phenethylamine
Phenmetrazine
Phentermine (+topiramate)
Phenylpropanolamine
Picilorex
Pipradrol
Prolintane
Propylhexedrine
Pseudoephedrine
Pyrovalerone
Radafaxine
Reboxetine
Setazindol
Sibutramine‡
Synephrine
Tesofensine
Viloxazine
Xylopropamine
Zylofuramine
Cannabinoid receptor antagonists
Drinabant§
Ibipinabant§
Otenabant§
Rimonabant‡
Rosonabant§
Surinabant§
Taranabant§
Others
5-HTP
Beloranib§
Galactomannan
Guar gum
Glucomannan
L-DOPA
L-Phenylalanine
L-Tryptophan
L-Tyrosine
Lorcaserin
Lu AA-33810
Metformin
Naltrexone
Naloxone
Oxyntomodulin
P57
Peptide YY
Topiramate
Velneperit§
Yohimbine (Yohimbe)
Zonisamide
Water
Peripheral
Cetilistat
2,4-Dinitrophenol‡
Dirlotapide
Mitratapide
Oleoyl-estrone
Orlistat
Simmondsin
Sterculia
#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
…PAH due to known risk factors, such as collagen vascular disease, congenital heart disease, or anorexigen use . Pneumothorax may result from unsuccessful attempts to inject drugs into the central circulation…
2. 成人の肺静脈閉塞症/肺毛細血管腫症の疫学、発症機序、臨床評価、診断epidemiology pathogenesis clinical evaluation and diagnosis of pulmonary veno occlusive disease pulmonary capillary hemangiomatosis in adults [show details]
…patients with PVOD than in patients with typical group 1 PAH (ie, pre-capillary PAH) In contrast, anorexigen exposure, which is a risk factor for the development of group 1 PAH, is rare in PVOD. The following…
English Journal
Knockout of Gnrh2 in zebrafish (Danio rerio) reveals its roles in regulating feeding behavior and oocyte quality.
Marvel MM, Spicer OS, Wong TT, Zmora N, Zohar Y.
General and comparative endocrinology. 2019 Apr;().
Many studies on Gnrh1, and the teleost Gnrh3, have elucidated the roles of these peptides in reproductive regulation. However, the role of the midbrain population of Gnrh, Gnrh2, has long been a mystery, despite its ubiquitous conservation in all jawed vertebrates except rodents. Previous behavioral
Oxidative grafting vs. monolayers self-assembling on gold surface for the preparation of electrochemical immunosensors. Application to the determination of peptide YY.
Guerrero S, Agüí L, Yáñez-Sedeño P, Pingarrón JM.
Talanta. 2019 Feb;193()139-145.
A comparison of the performance of two electrochemical immunosensors for the determination of the anorexigen biomarker peptide YY (PYY) is reported by using as scaffolds screen printed gold electrodes modified either by oxidative grafting of p-aminobenzoic acid (p-ABA) or by assembling of a 4-mercap
A free essential amino acid, L-tryptophan (TRP), administered through a diet or directly into the gut, decreases food intake by engaging neural mechanisms. The ability of intragastric TRP to cross into the general circulation and through the blood-brain barrier, at least partly underlies hypophagia.
Anorexigen (TNF-alfa, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients : their relationship with nutritional parameters
an·o·rex·i·gen (an-ō-rek'si-jĕn), Any drug used to reduce appetite. [anorexia + -gen] ... Also, authors such as Flier (2006) have demonstrated that BCAA, especially leucine, can act on central receptors and signal anorexigen peptide ...
Introduction Appetite suppressant use is now considered an important risk factor for the development of primary PH. An association between the anorexigen aminorex and PH was first reported in the 1960s, and aminorex ...